Journal of Chemical Health Risks

sanad.iau.ir/journal/jchr



ORIGINAL ARTICLE

Predicting COVID-19 Vaccine Acceptance Based on Mental Status, Trust in the Government, and Demographics among the Iranian

Seyedeh Asma Hosseini

Department of Psychology, Faculty of Education and Psychology, Alzahra University, Tehran, Iran

INTRODUCTION

The COVID-19 crisis continues to adversely influence the world that causes morbidity and mortality as well as severely disrupting societies and economies worldwide [1, 2].

There were more than 100 different COVID-19 vaccines, undergoing clinical trials or approved for use in some regions [3]. According to the successful clinical efficacy, several vaccines are currently approved or authorized for emergency usage [4-7]. Although, new variants and mutations in the Covid-19 virus decreased the clinical effectiveness of the authorized vaccines[8]. Vaccines effectively can prevent Covid-19 deaths and severe



diseases more than other medical technology [9]. Herd immunization programs can be successful when there are high rates of acceptance and coverage [10]. In the context of vaccination, general acceptance is essential as vaccine discovery [11]; the benefits of vaccination depend on the tendency of individuals to vaccine [12]. However, anti-vaccination beliefs and conspiracy have become developed [13]. Vaccine hesitancy is one of the main threats to health in global [14].

Distrust toward vaccines is existing until now and decreased the percent of the vaccination [15, 16]. Trust in the COVID-19 vaccine is necessary because of the possibility of the new mutations and pandemic surging [17]. But, emergency vaccine development for the Covid-19 disease increased the vaccine hesitancy [12].

There are diverse reports on the rate of COVID-19 vaccine acceptance around the world. A variety of components are correlated to the trust in the COVID-19 vaccine. Sociodemographics, voting behavior, and the levels of trust in the government can affect Covid-19 vaccine acceptance [17]. WHO reported six determinants of vaccination trust: Objectivity, competence, fairness, sincerity, consistency, and faith [18]. Also, studies reported that effective, proper, more localized, specific, and relevant public education could build more confidence in the COVID-19 vaccine [19]. Lack of trust in vaccines can be influenced by the political conspiracy [20]. The most trusted sources for COVID-19 information are experts and the government [21]. It is necessary for governments and managers that first try to building the trust of the general population to the vaccination, and then trigger the vaccination. One of the main components of hesitancy and confidence for vaccine acceptance is paying attention to the effect of people's emotions. Attention to emotions can help to complement other aspects of the dissemination and education of vaccines. Such as developing credibility and trust to scientific experts and health agencies, building safety as well as high standards during the production of it, and equitable injection of it. There are some reasons for refusal or hesitancy about distrust in COVID-19 vaccination such as fear and anxiety [22]. Covid-19 pandemic imposed the most large-scale public health crisis worldwide. In addition to physical health, global psychological health is also affected by COVID-19 [23].

Some of the emotional reactions to the pandemic are anxiety, fear, anger, and that is paired whit negative attitudes and uncertainty like xenophobia and racism [24].

Also, higher vaccine hesitancy was reported in the individuals with some psychological profiles. Vaccine hesitancy correlated to motivation, beliefs, awareness, and knowledge [25]. The type of vaccine can influence the determinants [26].

For designing suitable vaccination programs, knowledge about whether or not individuals are eager to get a vaccine against COVID-19 is essential [11]. In addition to developing an approved vaccine, it is also very important that it will receive vastly or not [27].

The present study aimed to evaluate the acceptance of a COVID-19 vaccine among the general population in Iran.

MATERIALS AND METHODS

This cross-sectional study was conducted in Tehran from June 2021 and December 2021, during the COVID-19 pandemic . Data were obtained by an electronic questionnaire through professional groups of social networks (Googleform). The samples were gathered by a simplified-snowball sampling method where requested candidate members were invited to pass the requests to their WhatsApp contacts. From 2050 records participants, 1208 participants agreed to complete forms and were included in the study. The object of the sampling was to be an agent of the Iran general population according to sex, age, education, income, and ethnicity. Inclusion criteria were age over 18 years, being literate, and had a Telegram and WhatsApp account with access to the internet using a computer or smartphone.

The protocol was approved by the Institutional Review Board (IRB) of Alzahra University.

Information regarding demographic characteristics, marriage status, employment status, and monthly income in Iranian Rial, trust in government, anxiety, depression, psychological well-being, and psychological distress were collected. Moreover, participants were asked how strongly they accepted with the following statement (5-point Likert Scale: 1 = strongly disagree to 5 = strongly agree): "If a vaccine becomes available and is recommended for me, I would get it"; this variable was

dichotomized to COVID-19 vaccine acceptance (0 = strongly disagree/disagree/neutral; 1 = agree/strongly agree). Also, trust in Iranian and foreign vaccines- two questions evaluated the extent of trust in Iranian and foreign Covid-19 vaccine.

A cover letter was provided containing the objectives of the present study, expectations, confidentiality, rights, voluntary participation, anonymity, and introduction of the researcher and scale provider. All participants signed an electronic consent form, and the questionnaire answers were kept anonymous. Participants were informed that they could stop answering questionnaires at any time. The survey was notified to the general population of Tehran through professional groups of social networks (Telegram and WhatsApp).

Anxiety symptoms were evaluated by the self-rating screening tool the GAD-7 questionnaire. It is a 7-item question, ranging from 0 (not at all) to three (nearly every day). The severity of extreme anxiety disorders (generalized anxiety disorder or panic disorder) is shown based on its total score: minimal (0-4), mild (5-9), moderate (10-14), and severe (15-21) [28].

Symptoms of depression were evaluated by self-rated screening tool PHQ-9 scale. It is a 9-item question based on depression symptoms scaled from 0 (not at all) to three (nearly every day). The participants report the frequency of symptoms experienced within the last two weeks. The severity of depression is classified into minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27) [29].

The mental health of individuals was assessed using the Mental Health Inventory (MHI-28; [30]) that is a short form of the 34-item Mental Health Scale [31]. It has 28-items that measure psychological well-being and psychological distress in a 5-Likert scale ranging from 1 (completely disagree) to 5 (completely agree).

A single item evaluated the Trust in government: "To

what extent do you trust in the government for Covid-19 vaccination of the society?" The responses were in a Likert scale ranged from 1 (none) to 7 (completely).

Statistical analysis

Data were analyzed using SPSS-20 software. Frequency, percent, means, Standard Deviation were presented for data description. Chi-2 test was used for assessing the relationship between qualitative variables. T independent test was used for comparing the mean of well-being and distress according to vaccine acceptance and refusal responses. To evaluate the relationship (odds ratios) of factors with COVID-19 vaccine acceptance as a dependent variable, logistic regression models were applied. A P-value less than 0.05 was considered statistically significant.

RESULTS

Overall, from 2050 invited records, 1208 participants (completion rate: 58.9%) completed the survey. Sample characteristics are shown in Table 1. The mean age of participants was 32.80±12.37 years and 70.7% of them were female. 34.2% of the participants were between 18-24 years, and 24.1% were between 24-34 years. 56.0% of the participants were currently married. 68.7% of the samples were employed. Those with bachelor's degrees represented 35.6% of the sample, and 23.84% had a master's degree. 26.7% of all participants earned Between 40 to 70 million Rial per month. 36.8% of participants completely trusted in government (Table 1). Also, participants' generalized anxiety disorder, patient health questionnaire, mental health inventory are outlined in Table 1. 11.7% and 7.2% of the participants had severe anxiety disorder and patient health disorder. The mean well-being of samples was 49.54±11.51. The mean Distress of samples was 36.39±12.66 (Table 1).

Table 1. Sociodemographic characteristics,	generalized anxiety disorder, j	patient health questionnaire, 1	mental health inventory.
--	---------------------------------	---------------------------------	--------------------------

Sex Sex Female 854(00.7%) 541 (63.3%) 168 (48.6%) 112 (52.4%) Male 346(28.6%) 267 (71.4%) 385 (45.1) 213 (24.9%) P-Value 0.008 0.274 0.009 Age 18-24 413 (41.2%) 256 (62.0%) 114 (42.6%) 121 (29.3%) 35-44 249 (20.0%) 106 (66.7%) 111 (44.6%) 77 (0.9%) 455 4 174 (14.4%) 114 (65.5%) 84 (48.3%) 14 (24.3%) 55 + 70 (5.8%) 55 (75.6%) 41 (85.3%) 15 (21.4) P-Value 0.011 0.018 0.349 Highest education 114 (45.5%) 94 (48.3%) 42 (27.5%) Sime colleg 60 (4.57%) 39 (65.0%) 12 (42.3%) 14 (42.3%) High school/Dploma 214 (17.2%) 12 (63.3%) 14 (42.5%) 12 (23.2%) Marcie dragree 423 (55.7%) 30 (69.45%) 14 (42.6%) 12 (23.2%) Marcie dragree 288 (23.4%) 198 (65.5%) 114 (45.6%) 12 (23.2%)	Items	N (%)	COVID-19 Vaccine Acceptance n (%)	Iranian COVID-19 Vaccine Acceptance n (%)	Foreign COVID-19 Vaccine Acceptance n (%)
Female \$\$41(63.3%) 168(48.6%) 112 (22.4%) Male 346(28.6%) 247(71.4%) 385 (45.1) 213 (24.9%) P-Value 0.008 0.274 0.009 Age 18-24 413 (34.2%) 256 (62.0%) 174 (42.6%) 121 (25.3%) 35-44 249 (20.6%) 166 (65.7%) 111 (44.6%) 77 (30.9%) 45-54 174 (14.4%) 114 (65.5%) 84 (48.3%) 44 (23.3%) 55* 70 (5.8%) 55 (78.6%) 41 (63.3%) 25 (27.5%) Finibled mandatory 91(7.3%) 54 (69.3%) 38 (41.8%) 25 (27.5%) Bigh-school/Diploma 214 (17.2%) 121 (65.5%) 91 (42.3%) 44 (23.6%) Some college 91(7.43%) 30 (69.4%) 38 (41.8%) 25 (27.5%) Bigh-school/Diploma 214 (17.2%) 121 (65.5%) 91 (42.5%) 44 (23.6%) Some college 91(7.43%) 30 (69.4%) 30 (69.4%) 122 (23.5%) 44 (23.6%) Married degree 432 (35.7%) 300 (69.4%) 140 (48.6%) 122 (23.5%)			Sex		
Mak340(28.0%)247 (71.4%)385 (45.1)213 (24.9%)V-late0.02740.02740.02740.0274IB-24413 (34.2%)256 (62.0%)174 (42.6%)121 (29.3%)35.442.19 (24.1%)195 (67.0%)119 (47.8%)66 (23.4%)35.442.19 (24.1%)116 (65.5%)111 (44.6%)77 (0.0%)35.5470 (5.8%)55 (78.0%)41 (63.5%)41 (23.5%)35.5470 (5.8%)55 (78.0%)41 (63.5%)41 (23.5%)FValue0.0380.0380.0380.025 (25.5%)Big chool/Diplom2.14 (17.2%)54 (59.3%)38 (41.5%)25 (27.5%)Big chool/Diplom2.14 (17.2%)30 (65.0%)21 (156.3%)21 (16.3%)21 (23.5%)Bachelor degree2.82 (23.8%)139 (68.0%)21 (14.8%)70 (27.4%)Bachelor degree2.82 (23.8%)139 (65.0%)21 (14.8%)70 (27.4%)Bachelor degree2.82 (23.8%)139 (65.0%)21 (14.8%)70 (27.4%)Bachelor degree2.82 (23.8%)139 (65.0%)21 (14.8%)70 (27.4%)Bachelor degree2.0010.3260.128 (23.4%)Bachelor degree2.90 (23.5%)323 (64.7%)236 (47.7%)218 (23.4%)Bachelor degree3.11 (65.0%)3.223 (64.7%)236 (47.5%)218 (23.4%)Bachelor degree3.11 (65.0%)5.87 (71.9%)236 (47.5%)219 (35.6%)Bachelor degree3.11 (65.0%)5.87 (71.9%)236 (47.5%)219 (35.6%)Bachelor degree	Female	854(70.7%)	541 (63.3%)	168 (48.6%)	112 (32.4%)
P-Value0.0080.2740.009AgeAge18:24413 (34.2%)256 (62.0%)114 (42.0%)121 (29.3%)25:44240 (20.0%)166 (66.7%)111 (44.0%)77 (30.9%)45:54174 (14.4%)114 (65.5%)84 (43.3%)44 (21.3%)45:54174 (14.4%)114 (65.5%)84 (43.3%)451 (21.2%)65:6597 (53.8%)55 (78.0%)41 (63.3%)63.09Palae0.0310.0380.390Palae0.0310.0380.390Backion degre91 (7.5%)121 (65.5%)91 (45.3%)25 (27.5%)18da coloregre91 (7.5%)121 (65.5%)91 (42.5%)44 (00.6%)Some college04 (47.9%)30 (60.4%)120 (21.8%)97 (7.4%)Backion degre288 (23.8%)198 (68.8%)211 (48.9%)79 (27.4%)Master degre288 (23.8%)198 (66.5%)49 (9.0.8%)42 (3.4%)P-Vate0.0190.0320.0710.003Backion degre431 (68.7%)52 (67.9%)236 (47.9%)158 (3.5%)Maried76 (56.0%)429 (66.5%)29 (41.7%)96 (31.1%)Widde930 (25.5%)187 (60.5%)29 (67.5%)218 (62.5%)Maried931 (68.7%)33 (66.0%)29 (67.5%)218 (62.0%)Widde391 (25.5%)160 (66.5%)29 (61.7%)218 (62.5%)Maried931 (68.7%)31 (66.0%)216 (15.8%)218 (15	Male	346(28.6%)	247 (71.4%)	385 (45.1)	213 (24.9%)
Age 18-24 413 (34.2%) 256 (62.0%) 174 (42.0%) 121 (29.3%) 25.44 291 (24.1%) 195 (67.0%) 139 (47.8%) 68 (23.4%) 35.44 249 (20.0%) 166 (65.7%) 111 (44.0%) 77 (30.9%) 45.54 174 (14.4%) 114 (65.5%) 84 (48.3%) 44 (23.3%) 55* 70 (5.8%) 55 (78.6%) 41 (85.3%) 15 (21.4) P-Value 0.031 0.038 0.349 Highest education Finished mandatory set (57.5%) 38 (41.8%) 25 (27.5%) Saturating 91(7.5%) 121 (65.3%) 91 (42.5%) 14 (20.6%) Saturating 91(7.5%) 30 (69.4%) 124 (42.6%) 122 (82.5%) Same college 60 (49.7%) 124 (20.8%) 124 (20.8%) 122 (82.5%) Master degree 228 (13.7%) 30 (69.4%) 336 (49.7%) 124 (24.8%) 79 (27.4%) Ph.D. 123 (10.1%) 80 (65.5%) 211 (48.8%) 79 (27.4%) 16 (24.4%)	Р-	Value	0.008	0.274	0.009
18-24 413 (34.2%) 256 (62.0%) 174 (42.0%) 121 (29.3%) 25.34 291 (24.1%) 195 (67.0%) 139 (47.8%) 68 (23.4%) 35.44 249 (20.6%) 166 (66.7%) 111 (44.6%) 77 (30.9%) 45.54 174 (14.4%) 114 (65.5%) 84 (48.3%) 14 (23.3%) 55* 70 (5.5%) 55 (78.6%) 41 (53.3%) 15 (21.4) PvNute 0.031 0.033 0.369 Highest education Finished mandatory schooling 91 (7.53%) 54 (59.3%) 38 (41.8%) 25 (27.5%) Bacheor degree 04 (97%) 39 (65.0%) 27 (45.0%) 14 (23.5%) Bacheor degree 288 (23.54%) 198 (68.8) 211 (48.6%) 122 (28.2%) Master degree 288 (23.54%) 198 (66.8%) 236 (49.7%) 158 (23.4%) PvD. 123 (01.18 80 (65.0%) 40 (64.4%) 236 (49.7%) 158 (23.4%) Married 676 (50.0%) 40 (66.4%) 336 (49.7%) 158 (23.4%) Nige 409 (66.4%)			Age		
25.34291 (24.1%)195 (67.0%)199 (47.8%)68 (23.4%)35.42.09 (20.6%)1.16 (65.7%)1.11 (44.5%)77 (20.9%)34.541.74 (1.44%)1.14 (65.5%)84 (4.64.3%)1.5 (21.4)55.70 (5.8%)55 (78.6%)44 (64.3%)1.5 (21.4)55.70 (5.8%)55 (78.6%)0.0380.340Fibiled mandback91 (7.53%)54 (9.3%)38 (41.8%)25 (27.5%)36 ohol/Fjoloma2.14 (7.7%)1.21 (65.3%)91 (42.5%)44 (20.3%)Some college0.01 (97.5%)3.00 (97.4%)1.41 (23.3%)79 (27.4%)36 backer degree2.28 (25.7%)3.00 (97.4%)1.41 (43.3%)79 (27.4%)36 backer degree2.88 (33.4%)1.98 (65.0%)4.41 (23.4%)1.21 (48.3%)79 (27.4%)37 backer degree2.88 (23.5%)1.98 (65.0%)4.91 (43.4%)4.23 (14.1%)37 backer degree2.88 (23.5%)1.98 (65.0%)4.91 (43.4%)1.58 (23.4%)38 backer degree2.88 (23.5%)1.98 (65.0%)4.91 (43.5%)1.58 (23.4%)39 backer degree3.03 (25.5%)2.91 (45.5%)1.58 (23.4%)1.58 (23.4%)30 backer degree2.89 (23.5%)2.81 (65.5%)2.92 (61.7%)2.93 (23.5%)30 backer degree3.51 (65.5%)4.91 (65.5%)2.92 (61.7%)2.93 (23.5%)30 backer degree3.51 (65.5%)3.53 (67.1%)3.53 (67.1%)3.53 (67.1%)3.53 (67.1%)30 backer degree3.51 (65.5%)3.53 (67.1%)3.53 (67.1%)3.6	18-24	413 (34.2%)	256 (62.0%)	174 (42.6%)	121 (29.3%)
35-44249 (20.6%)166 (65.7%)111 (44.6%)7 (30.9%)45.54174 (44.4%)114 (65.5%)44 (48.3%)44 (23.5%)55 (78.0%)41 (83.5%)55 (78.0%)41 (83.5%)0.38P-Value0.0310.0380.38Frisher dmandator schoolf/bjfoma91 (7.53%)54 (93.3%)38 (41.8%)25 (27.5%)High school/Djfoma214 (17.72%)121 (65.3%)91 (42.5%)44 (20.6%)Sone college60 (4.97%)39 (65.0%)27 (45.0%)(14 (23.5%)Bachelor degree228 (23.84%)198 (68.8)211 (48.8%)70 (27.8%)Ph.D123 (10.18)80 (65.0%)449 (36.8%)158 (23.4%)Order229 (10.3%)232 (46.7%)356 (49.7%)158 (23.4%)Single409 (41.3%)232 (46.7%)209 (41.9%)159 (31.9%)Vidow24 (20.5%)16 (65.0%)216 (63.7%)158 (23.4%)Single409 (25.5%)16 (65.0%)209 (41.9%)90 (31.1%)P-Value0.8290.0310.0080.119Immindi354 (29.3%)228 (41.4%)184 (50.7%)218 (26.2%)Single81 (68.7%)228 (41.4%)184 (50.5%)218 (26.2%)Immindi354 (29.3%)228 (41.4%)184 (50.7%)218 (26.2%)Immindi354 (29.3%)228 (41.4%)184 (50.7%)218 (26.2%)Immindi354 (29.3%)228 (41.4%)184 (50.5%)218 (26.2%)Immindi354 (29.3%)228 (41.4%)184 (50.7%)217 (27.6	25-34	291 (24.1%)	195 (67.0%)	139 (47.8%)	68 (23.4%)
45:54174 (14.4%)114 (65.%)84 (48.3%)44 (24.3%)55+70 (5.8%)55 (78.6%)41 (8.2%)15 (21.4)Finished mandator91 (7.53%)54 (9.3%)38 (41.8%)25 (27.5%)Finished mandator91 (7.53%)54 (9.3%)38 (41.8%)25 (27.5%)High school/Diploma214 (17.7%)121 (56.3%)91 (42.5%)44 (20.6%)Some college60 (4.97%)39 (65.0%)27 (45.0%)141 (23.3%)Bachelor degree238 (23.5%)300 (09.4%)140 (48.6%)122 (28.2%)Master degree238 (23.5%)300 (69.4%)49 (93.8%)42 (34.1%)Ph.D123 (0.18)80 (65.0%)49 (93.8%)42 (34.1%)Married676 (56.0%)449 (66.4%)360 (71.9%)(93.0%)Widow24 (20.%)16 (66.7%)209 (91.9%)99 (31.9%)Widow24 (20.8%)158 (67.1%)395 (47.5%)2018 (23.8%)Married676 (56.0%)449 (66.4%)305 (47.5%)209 (91.9%)Widow24 (20.8%)158 (67.1%)395 (47.5%)218 (20.2%)Numenployed300 (25.5%)158 (60.5%)209 (13.1%)90 (33.1%)Widow223 (0.13%)558 (67.1%)395 (47.5%)218 (20.1%)Minimi470 (28.7%)131 (65.6%)214 (40.1%)66 (31.1%)Minimi470 (28.7%)218 (67.6%)218 (62.8%)218 (62.8%)218 (62.8%)Minimi470 (28.7%)218 (66.6%)218 (62.8%)218 (62.8%)218 (62.8%)M	35-44	249 (20.6%)	166 (66.7%)	111 (44.6%)	77 (30.9%)
55+70 (5.8%)55 (78.6%)41 (58.3%)15 (21.4)P-Value0.0310.0380.349Inished mandatory school/Dipoma91(7.53%)54 (59.3%)38 (41.8%)25 (27.5%)High school/Dipoma214 (17.2%)121 (56.3%)91 (42.5%)41 40.0%)Some college0.00 (49.7%)300 (69.4%)140 (48.6%)122 (28.2%)Bachelor degree423 (25.7%)300 (69.4%)140 (48.6%)122 (28.2%)Master degree228 (23.84%)198 (68.5%)211 (48.8%)79 (27.4%)Ph.D123 (10.18)80 (65.0%)49 (9.3%)42 (34.1%)Origina70.9210.0190.20 (20.41)%)158 (23.4%)Married676 (56.0%)449 (66.4%)336 (49.7%)158 (23.4%)Single499 (41.3%)323 (64.7%)209 (41.9%)159 (31.9%)Widow24 (2.0%)16 (66.7%)70 (29.2%)9 (37.4%)Married676 (56.0%)439 (66.4%)395 (47.5%)218 (26.2%)Midow24 (2.0%)15 (65.7%)218 (26.2%)9 (31.4%)Single499 (41.3%)558 (77.1%)395 (47.5%)218 (26.2%)Midow230 (05.2%)16 (66.7%)29 (41.9%)9 (31.4%)Serier831 (68.7%)558 (77.1%)395 (47.5%)218 (26.2%)Midow230 (05.2%)16 (66.7%)29 (41.0%)9 (31.4%)Midow254 (29.3%)228 (64.4%)184 (52.0%)218 (26.2%)Midow254 (29.3%)218 (45.5%)228 (45.5%)22 (45-54	174 (14.4%)	114 (65.5%)	84 (48.3%)	44 (24.3%)
P-Value0.0310.0380.349Finished nandatory school/pioma01(7.5%)54 (59.3%)38 (41.8%)25 (27.5%)Finished nandatory school/pioma214 (17.72%)121 (56.3%)91 (42.5%)44 (20.6%)Bigh school/Diploma214 (17.72%)121 (56.3%)91 (42.5%)44 (20.5%)Some college66 (49.9%)300 (60.5%)141 (48.6%)122 (28.2%)Bachelor degree288 (23.4%)198 (66.8%)211 (48.6%)70 (27.4%)Ph.D123 (10.18)80 (65.0%)449 (39.8%)42 (24.1%)Ph.D123 (10.18)80 (65.0%)449 (39.8%)42 (24.1%)Married676 (56.0%)449 (64.9%)336 (49.7%)155 (31.9%)Single499 (41.3%)323 (47.%)209 (41.9%)155 (31.9%)Widow24 (2.0%)16 (66.7%)7 (29.2%)9 (37.4%)Widow24 (2.0%)18 (56.7%)218 (52.6%)90.002Widow24 (2.0%)187 (60.5%)124 (40.1%)96 (31.1%)Single330 (92.5%)187 (60.5%)124 (40.1%)96 (31.1%)Minemaphycel354 (92.5%)28 (64.4%)184 (52.0%)91 (19.5%)Inininal554 (71.3%)28 (64.4%)184 (52.0%)91 (19.5%)Inininal554 (92.5%)28 (64.5%)184 (52.0%)28 (13.6%)Inininal554 (92.5%)28 (64.5%)184 (52.0%)21 (25.5%)Inininal554 (92.5%)28 (64.5%)28 (41.0%)18 (35.3%)Inininal554 (92.5%)28 (55+	70 (5.8%)	55 (78.6%)	41 (58.3%)	15 (21.4)
Highest education Finished mandatory schooling 91(7.53%) 54 (59.3%) 38 (41.8%) 25 (27.5%) High school/Diploma 214 (17.72%) 121 (56.3%) 91 (42.5%) 44 (20.6%) Some college 60 (4.97%) 39 (65.0%) 27 (45.0%) 14 (23.3%) Bachelor degree 432 (35.76%) 300 (69.4%) 140 (48.6%) 122 (28.2%) Master degree 288 (23.84%) 198 (68.0%) 211 (48.8%) 79 (27.4%) Ph.D 123 (10.18) 80 (65.0%) 40 (38.9%) 42 (34.1%) P-Value 0.019 0.326 0.132 Married 676 (56.0%) 449 (66.4%) 336 (49.7%) 158 (23.4%) Widow 24 (2.0%) 16 (66.7%) 72 (2.2%) 9 (37.4%) P-Value 0.829 0.007 0.033 Employed 831 (68.7%) 558 (67.1%) 124 (40.1%) 96 (31.1%) Reired 47 (3.8%) 36 (76.6%) 29 (61.7%) 218 (26.2%) Married 64 (76.3%) 124 (60.1%) 96 (41.0%) 91 (91.1%)	Р-	Value	0.031	0.038	0.349
Finished mandatory schooling 91(7.53%) 54 (59.3%) 38 (41.8%) 25 (27.5%) High school/Diploma 214 (17.72%) 121 (56.3%) 91 (42.5%) 44 (20.6%) Some college 60 (4.97%) 39 (65.0%) 27 (45.0%) 14 (23.3%) Bachelor degree 432 (35.76%) 300 (69.4%) 140 (48.6%) 122 (28.2%) Master degree 288 (23.84%) 198 (68.8) 211 (48.8%) 70 (27.4%) Ph.D. 123 (10.18) 80 (65.0%) 49 (39.8%) 42 (34.1%) P-Value 0.019 0.326 0.132 Married 676 (56.0%) 449 (66.4%) 336 (49.7%) 158 (23.4%) Single 499 (41.3%) 233 (64.7%) 209 (41.9%) 159 (31.9%) Widow 24 (20.6%) 158 (67.1%) 395 (47.5%) 218 (26.2%) unemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) P-Value 0.031 0.008 0.119 Married 47 (38.%) 588 (67.1%) 284 (52.0%) 121 (26.5%) une			Highest education		
Instantoning Instantoning High school/Diploma 214 (17.7%) 121 (56.3%) 91 (42.5%) 44 (20.6%) Some college 60 (4 97%) 39 (65.0%) 27 (45.0%) 140 (48.6%) 122 (28.2%) Master degree 288 (23.84%) 198 (68.8) 211 (48.8%) 79 (27.4%) Ph.D 123 (10.18) 80 (65.0%) 49 (39.8%) 42 (34.1%) PValue 0.019 0.326 0.312 Constrained 676 (56.0%) 449 (66.4%) 33 (64.7%) 158 (23.4%) Single 499 (41.3%) 323 (64.7%) 209 (41.9%) 159 (31.9%) Widow 24 (2.0%) 16 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 unenployed 309 (57.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Iunenployed 309 (57.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (11.4%) 9(19.1%) ninininal 554 (29.3%) 160 (66.5%) 92	Finished mandatory	91(7.53%)	54 (59.3%)	38 (41.8%)	25 (27.5%)
Instrument Inputtion Interface Interface Interface Interface Interface Some college 60 (4.97%) 39 (65.0%) 27 (45.0%) 14 (23.3%) Bachelor degree 288 (23.84%) 198 (68.8) 211 (48.8%) 79 (27.4%) Ph.D. 123 (10.18) 80 (65.0%) 49 (39.8%) 42 (24.1%) P-Value 0.019 0.326 0.132 Married 676 (56.0%) 449 (66.4%) 336 (49.7%) 158 (23.4%) Single 499 (41.5%) 232 (64.7%) 209 (41.9%) 159 (31.9%) Widow 24 (2.0%) 16 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 umenployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (40.1%) 9 (19.1%) niminal 547 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) nidecrife 47 (3.8%) 28 (65.5%) 222 (46.3%) 127 (26.5%) moderate	scnooling High school/Diploma	214 (17 72%)	121 (56 3%)	91 (42 5%)	44 (20.6%)
Banchelor degree 432 (35.76%) 370 (05.9%) 12 (48.6%) 122 (28.2%) Master degree 288 (23.87%) 198 (68.8) 211 (48.8%) 79 (27.4%) Ph.D 123 (10.18) 80 (65.0%) 49 (39.8%) 42 (34.1%) P-Value 0.019 0.326 0.132 Married status Married status Married 676 (56.0%) 449 (66.4%) 336 (49.7%) 158 (23.4%) Single 499 (41.3%) 323 (64.7%) 209 (41.9%) 159 (31.9%) Widow 24 (2.0%) 16 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 Imployment status Employed 831 (68.7%) 558 (67.1%) 395 (47.5%) 218 (26.2%) unemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 91 (19.8%) minimal 554 (67.9%) 218 (52.0%) 70 (19.8%) midd 479 (39.7%)	Some college	60 (4 97%)	39 (65.0%)	27 (45.0%)	14(23.3%)
Martene tegree 2.82 (2.3.4%) 3.00 (05.4%) 1.40 (48.3%) 7.92 (2.4%) Master degree 2.88 (2.3.4%) 1.98 (68.3) 2.11 (48.8%) 7.92 (2.4%) Ph.D. 1.23 (10.18) 80 (65.0%) 49 (39.8%) 42 (3.4.1%) P-Value 0.019 0.326 0.132 Married 676 (56.0%) 449 (66.4%) 336 (49.7%) 1.58 (23.4%) Single 4.99 (41.3%) 323 (64.7%) 209 (41.9%) 1.59 (31.9%) Widow 2.4 (2.0%) 1.6 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 memployed 305 (47.5%) 218 (26.2%) unemployed 309 (25.5%) 1.87 (60.5%) 124 (40.1%) 96 (31.1%) P-Value 0.031 0.008 0.119 minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) midd 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) midd 479 (39.7%) 314 (65.6%) 223 (10.8%) 81 (33.9%)	Bachalar dograa	432 (35 76%)	300 (69.4%)	27 (45.0%)	14(23.3%)
Inside togic 2.68 (2.5.4×6) 1.19 (0.6.5) 2.11 (06.5%) 1.9 (2.1×6) Ph.D. 1.23 (10.18) 80 (65.0%) 49 (39.8%) 42 (34.1%) P-Value 0.019 0.326 0.132 Married 676 (56.0%) 449 (66.4%) 336 (49.7%) 158 (23.4%) Single 499 (41.3%) 323 (64.7%) 209 (41.9%) 159 (31.9%) Widow 24 (2.0%) 16 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 Employment status Employed 831 (68.7%) 558 (67.1%) 395 (47.5%) 9 (19.1%) p-Value 0.031 0.008 0.119 P-Value 0.031 0.008 0.119 minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mid 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 100 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%)	Master dogree	432(33.76%)	108 (69.9)	(48.0%)	122(28.2%)
Fib. 12 (10.18) 80 (00.08) 49 (53.88) 42 (54.18) P-Value 0.019 0.326 0.132 Married 676 (56.0%) 449 (66.4%) 336 (49.7%) 158 (23.4%) Single 499 (41.3%) 323 (64.7%) 209 (41.9%) 159 (31.9%) Widow 24 (2.0%) 16 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 Employed 831 (68.7%) 558 (67.1%) 395 (47.5%) 218 (26.2%) unemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 Minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mid 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) mid 479 (39.7%) 314 (66.6%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (35	Dh D	122 (10.18)	20 (65 0%)	40 (20.8%)	13(21.470)
Invite 0.019 0.520 0.132 Married 676 (56.0%) 449 (66.4%) 336 (49.7%) 158 (23.4%) Single 499 (41.3%) 323 (64.7%) 209 (41.9%) 159 (31.9%) Widow 24 (2.0%) 16 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 Employment status 218 (26.2%) 118 (23.6%) 218 (26.2%) unemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 Anxiety disorder minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) midd 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (55.3%) Minimal 409 (33.9%) 268 (65.	ГШ.Д.	125 (10.18)	0.010	49 (39.8%)	42 (34.1%)
Married 676 (56.0%) 449 (66.4%) 336 (49.7%) 158 (23.4%) Single 499 (41.3%) 323 (64.7%) 209 (41.9%) 159 (31.9%) Widow 24 (2.0%) 16 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 Employment status Employed 831 (68.7%) 588 (67.1%) 395 (47.5%) 218 (26.2%) unemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 Maxiety disorder minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mild 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (53.3%) P-Value 0.933 0.013 <0.001	· ·	value	0.019 Monited status	0.520	0.152
Married 676 (56.0%) 449 (66.4%) 536 (47.7%) 138 (25.4%) Single 499 (41.3%) 323 (64.7%) 209 (41.9%) 159 (31.9%) Widow 24 (2.0%) 16 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 Employed 831 (68.7%) 558 (67.1%) 395 (47.5%) 218 (26.2%) Imemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.3%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mild 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (55.3%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 05 (271.9%) Mild 387 (32.0%) 248 (65.5%)	Mound	676 (56 00/)		226 (40.70/)	159 (22 40/)
Single 499 (41.5%) 3.23 (64.7%) 2.09 (41.9%) 159 (31.9%) Widow 24 (2.0%) 16 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 Employment status 200 (41.9%) 218 (26.2%) Immemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 Minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mild 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (53.3%) P-Value 0.933 0.013 <001 Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) <	Married	676 (56.0%)		336 (49.7%)	158 (23.4%)
Widow 24 (2.0%) 16 (66.7%) 7 (29.2%) 9 (37.4%) P-Value 0.829 0.007 0.003 Employment status 558 (67.1%) 395 (47.5%) 218 (26.2%) unemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 Anxiety disorder minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) midd 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (53.3%) P-Value 0.933 0.013 <0.001 Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Mideratel 189 (15.6%) 133 (70	Single	499 (41.3%)	323 (64.7%)	209 (41.9%)	159 (31.9%)
P-Value 0.829 0.007 0.003 Employed 831 (68.7%) 558 (67.1%) 395 (47.5%) 218 (26.2%) unemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 Anxiety disorder minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mild 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (55.3%) Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Minimal 89 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%)	Widow	24 (2.0%)	16 (66.7%)	7 (29.2%)	9 (37.4%)
Employment status Employed 831 (68.7%) 558 (67.1%) 395 (47.5%) 218 (26.2%) unemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 Anxiety disorder minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mild 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (55.3%) P-Value 0.933 0.013 <0.001 Depression Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 65 (34.4%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe	P-	Value	0.829	0.007	0.003
Employed 831 (08.%) 558 (6/.%) 395 (4/.5%) 218 (26.2%) unemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 Anxiety disorder minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) moderate 239 (19.8%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (55.3%) P-Value 0.933 0.013 <0.001 Depression Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) <th< td=""><td></td><td>001 (60 704)</td><td>Employment status</td><td>005 (15 50)</td><td>210 (26.201)</td></th<>		001 (60 704)	Employment status	005 (15 50)	210 (26.201)
unemployed 309 (25.5%) 187 (60.5%) 124 (40.1%) 96 (31.1%) Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mild 479 (39.7%) 214 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (55.3%) P-Value 0.933 0.013 <0.001 Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) Moderately severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%)	Employed	831 (68.7%)	558 (67.1%)	395 (47.5%)	218 (26.2%)
Retired 47 (3.8%) 36 (76.6%) 29 (61.7%) 9 (19.1%) P-Value 0.031 0.008 0.119 Anxiety disorder 70 (19.8%) minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mild 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (35.3%) P-Value 0.933 0.013 <0001 Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	unemployed	309 (25.5%)	187 (60.5%)	124 (40.1%)	96 (31.1%)
P-Value 0.031 0.008 0.119 Anxiety disorder Anxiety disorder 70 (19.8%) mild 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mild 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (35.3%) P-Value 0.933 0.013 <0.001 Depression 2001 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	Retired	47 (3.8%)	36 (76.6%)	29 (61.7%)	9 (19.1%)
Mixety disorder minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mild 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (35.3%) P-Value 0.933 0.013 <0.001 Depression Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	Р-	Value	0.031	0.008	0.119
minimal 354 (29.3%) 228 (64.4%) 184 (52.0%) 70 (19.8%) mild 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (35.3%) P-Value 0.933 0.013 <0.001 Depression Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001		254 (20.200)	Anxiety disorder	104 (50 000)	5 0 (10 00()
mild 479 (39.7%) 314 (65.6%) 222 (46.3%) 127 (26.5%) moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (35.3%) P-Value 0.933 0.013 <0.001 Depression 218 (53.3%) 72 (17.6%) Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	minimal	354 (29.3%)	228 (64.4%)	184 (52.0%)	70 (19.8%)
moderate 239 (19.8%) 160 (66.9%) 98 (41.0%) 81 (33.9%) severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (35.3%) P-Value 0.933 0.013 <0.001 Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	mild	479 (39.7%)	314 (65.6%)	222 (46.3%)	127 (26.5%)
severe 136 (11.3%) 90 (66.2%) 52 (38.2%) 48 (35.3%) P-Value 0.933 0.013 <0.001 Depression 218 (53.3%) 72 (17.6%) Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	moderate	239 (19.8%)	160 (66.9%)	98 (41.0%)	81 (33.9%)
P-Value 0.933 0.013 <0.001 Depression 218 (53.3%) 72 (17.6%) Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	severe	136 (11.3%)	90 (66.2%)	52 (38.2%)	48 (35.3%)
Minimal 409 (33.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	Р-	Value	0.933	0.013	<0.001
Minimal 409 (53.9%) 268 (65.5%) 218 (53.3%) 72 (17.6%) Mild 387 (32.0%) 244 (63.0%) 172 (44.4%) 105 (27.1%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%)	X(* * *	400 (22 02/)		019 (52 0%)	70 (17 (0))
Mild 587 (52.0%) 244 (65.0%) 172 (44.4%) 105 (27.1%) Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	Minimal	409 (33.9%)	208 (65.5%)	218 (33.3%)	/2 (1/.6%)
Moderate 189 (15.6%) 133 (70.4%) 84 (44.4%) 65 (34.4%) Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	Mild	387 (32.0%)	244 (63.0%)	1/2 (44.4%)	105 (27.1%)
Moderately severe 136 (11.3%) 92 (67.6%) 51 (37.5%) 52 (38.2%S) Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	Moderate	189 (15.6%)	133 (70.4%)	84 (44.4%)	65 (34.4%)
Severe 87 (7.2%) 55 (63.2%) 31 (35.6%) 32 (36.8%) P-Value 0.479 0.002 <0.001	Moderately severe	136 (11.3%)	92 (67.6%)	51 (37.5%)	52 (38.2%S)
P-Value 0.479 0.002 <0.001	Severe	87 (7.2%)	55 (63.2%)	31 (35.6%)	32 (36.8%)
	Р-	Value	0.479	0.002	< 0.001

<10 million	199 (16.5%)		124 (62.3%)	90 (45.2%)	48 (24.1%)
10-30 million	146 (12.1%)		87 (59.6%)	61 (41.8%)	33 (22.6)
40-70 million	323 (26.7%)		215 (66.6%)	152 (47.2%)	81 (25.1%)
80-110 million	175 (14.5%)		122 (69.7%)	78 (44.6%)	62 (35.4%)
>120 million	98 (8.1%)		76 (77.6%)	52 (53.1)	38 (38.8%)
Р-	Value		0.028	0.501	0.004
		Trust in go	overnment		
None	173 (14.3%)		123 (71.1%)	19 (11.0%)	120 (69.4%)
Very low	36 (3.0%)		21 (58.3%)	8 (22.2%)	19 (52.8%)
low	39 (3.2%)		24 (61.5%)	9 (23.1%)	20 (51.3%)
Moderate	110 (9.1%)		64 (58.2%)	36 (32.7%)	44 (40.0%)
High	136 (11.3%)		68 (50.0%)	41 (31.6%)	36 (26.5%)
Very high	268 (22.2%)		171 (63.8%)	144 (53.7%)	51 (19.0%)
Completely	445 (36.8%)		321 (72.1%)	297 (66.7)	36 (8.1%)
P-	Value		< 0.001	< 0.001	< 0.001
		Mental healt	th inventory		
W/-11 h -t	40.54.11.51	No	49.17±11.33	47.40±11.75	51.13±11.00
weii-being	49.54±11.51	Accept	49.73±11.60	52.04±10.69	45.22±11.76
Р-	Value		0.420	< 0.001	< 0.001
Distances	26 20 1 12 66	No	36.33±12.66	38.33±12.93	34.84±12.36
Distress	30.39±12.00	Accept	36.42±12.68	34.12±11.96	40.59±12.55
Р-	Value		0.911	< 0.001	< 0.001

Acceptance of COVID-19 vaccine

Of the 1209 participants surveyed, 792 (66.56%) reported that they would accept a COVID-19 vaccine if it is recommended for them. Then, 46.03% and 26.99% of

participants reported that they preferred an Iranian vaccine and a foreign vaccine respectively (Figure 1).



Figure 1. A) Distribution of rates of COVID-19 vaccine acceptance, hesitance, and resistance; B) Distribution of rates of Iranian COVID-19 vaccine acceptance, hesitance, and resistance; C) Distribution of rates of foreign COVID-19 vaccine acceptance, hesitance, and resistance

Male participants were more likely to accept the vaccine compared to females (71.4% vs. 63.3%), older adults (>55 years; 78.6%) compared to younger adults, retired participants (81%) compared to other participants groups, and college and/or graduate degree holders (>65%) compared to people with less than a college degree more likely to accept the vaccine, participants with more income per month (>120 million Rial) had more vaccine acceptance rate (77.6%) compared to other

participants groups, participants who said that they completely trusted their government had more vaccine accept rate (72.1%) compare to others participants.

The Iranian vaccine acceptance in psychological characteristics was greater in the minimal anxiety disorder group (52.0%) compared to other participants groups, but, in those who said that they would accept a foreign COVID-19 vaccine if it is recommended for them in the severe anxiety disorder group (35.3%) was

greater compared to other participants groups. Also, the Iranian vaccine acceptance was highest in the minimal patient health group (53.3%) compared to other participants groups, but, in those who said that they would accept a foreign COVID-19 vaccine if it is recommended for them in the severe anxiety disorder group (36.8%) was greater compared to other participants groups.

The mean well-being score in the accepted Iranian vaccine was greater than those who refused it (P<0.001), but, and the mean well-being score in the accepted foreign vaccine were less than those who refused it (P<0.001). The mean distress score in accepted Iranian vaccine was less than those who refused it (P<0.001), but, and the mean distress score in the accepted foreign vaccine were higher than those who refused it (P<0.001). Additional investigation by multiple logistic regression

was accomplished to determine predictors of COVID-19 vaccine acceptance among participants. Table 2-4 summarizes the results for the logistic regressions. The regression model was completely described between 7% (Cox and Snell R Square) and 9.7% (Nagelkerke R Square) of variance in COVID-19 vaccine acceptance and correctly classified 70.0% of the samples.

As revealed in Table 2, only five variables made a statistically significant impact on the model. The strongest predictor of COVID-19 vaccine acceptance was trust in government, income, gender, well-being, and education.

The regression model for as a complete described between 20% (Cox and Snell R Square) and 27% (Nagelkerke R Square) of variance in Iranian COVID-19 vaccine acceptance and correctly classified 68.9% of the samples.

Tabl	e 2.	Logistic	regression	outputs for	r vaccine	acceptability	and demogr	aphics and	phycology	characteristics
		<i>u</i>	<i>U</i>					1	1 2 02	

	Terms		D CE Wald		ld Dyalua	Evn (B)	95% C.I. for EXP(B)	
	Items	Б	5.E.	waid	P-value	Ехр (Б)	Lower	Upper
	Gender	.407	.163	6.184	0.013	1.502	1.090	2.069
	Age			1.583	0.812			
	18-24	290	.452	.413	0.521	.748	.308	1.814
	25-34	334	.420	.631	0.427	.716	.314	1.632
	35-44	464	.411	1.278	0.258	.629	.281	1.406
	45-54	420	.407	1.064	0.302	.657	.296	1.459
	Married status			.801	0.670			
	Single	.155	.221	.497	0.481	1.168	.758	1.800
	Widow	.320	.514	.387	0.534	1.377	.503	3.767
	Education			12.30	0.031			
	Finished mandatory schooling	0.017	0.481	0.001	0.971	1.017	0.396	2.610
	High school/Diploma	124	.380	.106	0.745	.884	.420	1.860
Vaccine	Some college	.582	.346	2.82	.093	1.789	.907	3.528
	Bachelor degree	.343	.355	.933	.334	1.409	.703	2.826
	Master degree	.020	.392	.003	.958	1.021	.474	2.199
	Job			2.25	.323			
	unemployed	312	.240	1.693	.193	0.732	0.457	1.171
	Retired	.337	.461	.534	.465	1.401	.567	3.461
	Income Level			11.89	0.018			
	10-30 million	462	.261	3.121	.077	.630	.378	1.052
	40-70 million	.066	.228	.083	.773	1.068	.683	1.668
	80-110 million	.079	.266	.088	.766	1.082	.642	1.824
	>120 million	0.661	0.327	4.07	.043	1.936	1.019	3.678
	Trust In Government			18.56	.005			
	None	.079	.262	.091	.763	1.082	.648	1.808

Very low	456	.413	1.217	.270	.634	.282	1.425
low	522	.417	1.563	.211	.594	.262	1.345
Moderate	366	.272	1.802	.179	.694	.407	1.183
High	920	.240	14.66	< 0.001	.398	.249	.638
Very high	355	.195	3.30	.069	.701	.478	1.028
Anxiety			1.006	.800			
minimal	340	.373	.831	.362	.712	.343	1.478
mild	329	.331	.987	.320	.720	.376	1.377
moderate	233	.313	.55	.456	.792	.429	1.462
Patient Health			3.89	.420			
minimal	296	.439	.455	.500	.744	.315	1.758
mild	275	.392	.491	.483	.760	.353	1.637
moderate	.172	.384	.202	.653	1.188	.560	2.522
moderately severe	.105	.375	.078	.780	1.111	.532	2.318
Well-being	.025	.011	5.22	.022	1.025	1.004	1.048
Distress	.011	.011	.927	.336	1.011	.989	1.033
Constant	733	.852	.740	.390	.481		

Table 3. Logistic regression outputs for Iranian vaccine acceptability and demographics and phycology characteristics

Items		P	SF	Wold	Sig	Sig. Exp(B)	95% C.I.for EXP(B)		
1	tems	Б	5.E.	walu	51g.	Exp(B)	Lower	Upper	
	Gender	.284	.165	2.944	.086	1.328	.960	1.837	
	Age			3.534	.473				
	18-24	.327	.438	.556	.456	1.386	.587	3.272	
	25-34	013	.403	.001	.974	.987	.448	2.175	
	35-44	206	.394	.273	.602	.814	.376	1.762	
	45-54	.025	.390	.004	.949	1.025	.478	2.200	
	Married status			.989	.610				
	Single	.063	.228	.076	.782	1.065	.682	1.664	
	Widow	537	.575	.871	.351	.585	.189	1.805	
	Education			14.916	0.011				
	Finished mandatory schooling	.038	.497	.006	.939	1.038	.392	2.751	
	High school/Diploma	.404	.397	1.035	.309	1.497	.688	3.259	
Iranian Vaccine	Some college	0.755	0.358	4.460	0.035	2.128	1.056	4.288	
	Bachelor degree	.528	.366	2.073	.150	1.695	.827	3.475	
	Master degree	131	.406	.104	.747	.877	.395	1.946	
	Job			3.265	.195				
	unemployed	310	.249	1.550	.213	.733	.450	1.195	
	Retired	.559	.437	1.635	.201	1.749	.742	4.118	
	Income Level			8.796	.066				
	10-30 million	241	.273	.781	.377	.786	.460	1.341	
	40-70 million	.065	.231	.078	.780	1.067	.678	1.679	
	80-110 million	.196	.272	.516	.473	1.216	.713	2.073	
	>120 million	.707	.317	4.957	.026	2.028	1.088	3.777	
	Trust In Government			111.34	< 0.001				
	None	-2.822	0.327	74.46	< 0.001	0.059	0.031	.113	

Very low	-1.821	0.448	16.51	< 0.001	0.162	0.067	.389
low	-2.590	0.566	20.89	< 0.001	0.075	0.025	.228
Moderate	-1.183	0.272	18.92	< 0.001	0.306	0.180	.522
High	-1.507	0.250	36.31	< 0.001	0.222	0.136	.362
Very high	567	0.188	9.068	< 0.001	0.567	0.392	.821
Anxiety			.349	.951			
minimal	073	.377	.037	.847	.930	.445	1.945
mild	146	.336	.188	.665	.865	.448	1.670
moderate	144	.319	.203	.652	.866	.464	1.617
Patient Health			1.291	.863			
minimal	128	.458	.078	.780	.880	.359	2.158
mild	171	.412	.172	.678	.843	.376	1.890
moderate	.111	.398	.078	.780	1.118	.513	2.437
moderately severe	074	.403	.033	.855	.929	.421	2.047
Well-being	.024	.012	4.110	.043	1.024	1.001	1.047
Distress	.002	.012	.038	.846	1.002	.979	1.026
Constant	-2.168	.931	5.419	.020	.114		

As revealed in Table 3, only four variables made a statistically significant impact on the model. The strongest predictors of Iranian COVID-19 vaccine acceptance were "trust in government", income, well-being, and education.

The regression model for as a complete described between 26% (Cox and Snell R Square) and 38% (Nagelkerke R Square) of variance in Iranian COVID-19 vaccine acceptance and correctly classified 80.0% of the samples.

As revealed in Table 4, only three variables made a statistically significant impact on the model. The strongest predictors of Iranian COVID-19 vaccine acceptance were trust in government, gender and education.

Table 4. Logistic regression out	puts for foreign vaccine	acceptability and dem	nographics and phyco	ology characteristics
----------------------------------	--------------------------	-----------------------	----------------------	-----------------------

	Itoms	B	SF	S.E. Wald	Sig	Evp(B)	95% C.I. fo	or EXP(B)
	rums	Б	5. E.	vv alu	51g.	Exb(p)	Lower	Upper
	Gender	0.470	0.191	6.047	0.014	1.600	1.100	2.328
	Age			1.938	.747			
	18-24	017	.547	.001	.975	.983	.336	2.871
	25-34	074	.500	.022	.882	.928	.349	2.472
	35-44	.200	.479	.174	.676	1.221	.478	3.121
	45-54	170	.478	.126	.723	.844	.331	2.156
	Married status			1.806	.405			
	Single	.121	.274	.195	.659	1.128	.660	1.929
Foreign	Widow	.789	.603	1.713	.191	2.200	.675	7.167
Vaccine	Education			13.662	.018			
	Finished mandatory schooling	.457	.606	.570	.450	1.579	.482	5.176
	High school/Diploma	736	.525	1.970	.160	.479	.171	1.339
	Some college	.232	.457	.259	.611	1.261	.515	3.086
	Bachelor degree	.174	.469	.137	.711	1.190	.474	2.985
	Master degree	.653	.502	1.692	.193	1.921	.718	5.140
	Job			.523	.770			
	unemployed	.120	.288	.173	.677	1.127	.641	1.981

Retired	315	.537	.343	.558	.730	.255	2.092
Income Level			7.002	.136			
10-30 million	503	.343	2.149	.143	.605	.308	1.185
40-70 million	.013	.284	.002	.963	1.013	.580	1.770
80-110 million	.185	.320	.335	.563	1.204	.643	2.255
>120 million	.467	.367	1.626	.202	1.596	.778	3.274
Trust In Government			134.375	< 0.001			
None	3.396	.319	113.087	< 0.001	29.845	15.960	55.809
Very low	2.858	.451	40.171	< 0.001	17.434	7.203	42.198
low	2.951	.466	40.149	< 0.001	19.121	7.676	47.634
Moderate	2.230	.332	45.076	< 0.001	9.298	4.849	17.826
High	1.693	.321	27.815	< 0.001	5.433	2.897	10.191
Very high	1.228	.282	19.012	< 0.001	3.413	1.966	5.927
Anxiety			1.100	0.777			
minimal	427	.436	.958	0.328	.652	.277	1.535
mild	340	.372	.835	0.361	.712	.344	1.475
moderate	172	.342	.253	0.615	.842	.431	1.646
Patient Health			2.383	0.666			
minimal	637	.518	1.511	0.219	0.529	0.191	1.461
mild	354	.454	.606	0.436	0.702	0.288	1.710
moderate	249	.431	.335	0.563	0.779	0.335	1.813
moderately severe	050	.420	.014	0.904	0.951	0.417	2.167
Well-being	.003	.013	.053	.817	1.003	0.978	1.029
Distress	.008	.013	.391	.532	1.008	0.982	1.035
Constant	617	1.003	0.379	0.538	0.540		

DISCUSSION

The results of the present study showed that a majority of participants (66.56%) from across Tehran would like to accept a COVID-19 vaccine; however, this level of acceptance may not be adequate based on some of the estimates COVID-19 herd immunity. The herd immunity point for COVID-19 is evaluated to be between 55% and 82% [32]. Actual complete vaccination until February 2022 was 65% in Iran. The current estimation is very close to the real condition. However, acceptance was high, with 46.03% and 26.99% having to intend to have the Iranian and foreign vaccine respectively. There are several COVID-19 vaccines to achieve herd immunity through substantial vaccination, the acceptance and hesitancy of a COVID-19 vaccine must comprehend to improve evidence-based interventions. This will permit health administrators to progress messaging to best address concerns and inform all people.

There are diverse reports on the rate of COVID-19 vaccine acceptance around the world. One study in seven

European nations reported that the resistance or hesitancy to the COVID-19 vaccine was 26% [11], and delay in vaccination and refusal it is contributing to decreasing immunization rates [33]. In a study in Germany, 64.5% were reported that they will accept the COVID-19 vaccine, 13.8% reported will rather accept it, 10.4% reported they have no decision, and 5.2% reported they will rather not, and 6% reported they absolutely will not get the vaccine [34]. Vaccine hesitancy percent in Ireland and the United Kingdom were 35% and 31% respectively [16]. Only 36.1% of Australians declared that they were likely to get the COVID-19 vaccine [17]. Also, a noticeable percentage of the United States general population showed refuse or be unsure about getting the COVID-19 vaccine, and the hesitancy percent was 33% [35]. In another study, 69% of the United States population were eager to get a COVID-19 vaccine [36]. In Arab countries, the rate of acceptance of vaccines was 62.4% [37]. The largest survey in South Africa on

individual's willingness to get a COVID-19 vaccine showed that 67% of people will take a vaccine, 18% will not take the vaccine, and 15% had no decision about the vaccine [38]. An international study showed that the percent of vaccine acceptance was 76.4% (for 90% vaccine effectiveness) to 88.8% (for 95% vaccine effectiveness) [39]. Another global survey study reported that the potential acceptance of the COVID-19 vaccine was well (55-89%) [40]. The vaccine acceptance rate in the different regions was almost similar. A high acceptance rate in a community suggests vaccination can be effective and successful; however, recognizing factors in hesitant people is a priority for developing interventions. Demographic variables have been studied in the present study due to their undeniable effects on vaccine trust. The results of the current study showed that COVID-19 vaccine acceptance can be predicted with relatively high accuracy by readily available demographic characteristics. The acceptance rate increased with age and education level, and male sex. It increased with financial income, and among retired and employed participants. Clinical and scientific evidence was most accepted, with sociodemographic differences for different sources. According to some studies, demographic variables affect the degree of trust in the vaccine. Compared to participants accepting of a COVID-19 vaccine, females were more expected to be vaccine-hesitant, a finding consistent with several studies identifying sex-related differences in vaccine acceptance [17, 37, 39, 41, 42]. Consistent with previous studies, reluctance to vaccinate is higher between low age [17, 38, 41, 42]. The vaccine hesitancy was higher between lower-income people in another study [16].

The present study showed that the acceptance of the Covid-19 vaccine and Iranian Covid-19 vaccine increased among those with the highest trust in government. But, between those who did not trust in the government, the foreign Covid-19 vaccine was more acceptable.

Political dependency can have an impact on trust in the vaccine [43]. Lack of trust in vaccines influenced by the political conspiracy [20]. Disillusionment with authorities is a strong predictor of attitudes about the vaccine [44]. Great trust in government sources of information about COVID-19 is correlated to obedience

in social distancing and exact COVID-19 knowledge [45]. The information coming from political officials has an impact on responses to orders of government [46]. There was a strong correlation between distrust in authorities and distrust in the vaccine [17]. Having higher conspiracy beliefs is associated to lower adherence to containment-related behavior via a reduced political trust [47].

In the results of the current study, the well-being score was higher in those who had vaccine acceptance. One of the essential components of the hesitancy and trust in the vaccine is the function of emotions such as anger, fear, and happiness. Attention to emotions can help to complement other important aspects of the dissemination and education of vaccines. There are some reasons for refusal or hesitancy in COVID-19 vaccination such as fear and anxiety [16, 22, 34, 39, 48, 49].

The current results about Iranian Covid-19 are consist with vaccine hesitancy is higher in people that are suffering from depression and anxiety [50]. Poor health behaviors, depression, stress, and loneliness can weaken the immune system's response to the vaccine [51]. Generally, given that investigating the psychological stems of vaccine hesitancy is very important for reaching large vaccination rates [52], researching how various ideological groups behave in contact to disease threat is very important for both practical and theoretical reasons, and there are few guiding theories about the interface of disease outbreaks and ideology [53], understanding the ways to can have effective orders for peoples is important for governments [46]. A study showed that social and religious leaders can pose as agents of transformation [54].

In the current study, trust in an Iranian Covid-19 vaccine was higher than a foreign vaccine. Community leaders' views on vaccination can influence people's opinions [55]. Leaders can change people's opinions. One of the important ways for increasing the acceptance of vaccines is the engagement of religious leaders [56]. The frequent and early engagement of community and religious leaders is the key to the readiness of the COVID-19 vaccine. Authorities that voluntarily get the COVID1-19 vaccine increase the trust level among the general population [57]. On June 25, 2021, the Supreme Leader of Iran, Ayatollah Khamenei has received the first vaccine dose of COVID-19. The Vaccine was produced by Iranian Scientists inside Iran (COV-Iran Barekat vaccine). He also stated that he did not want to use the foreign vaccine and preferred to wait for the Iranian vaccine to be made to use.

Many studies suggest that the political attitudes affect apolitical outcomes [58], but the knowledge about it is few [59], and the findings of the vaccine hesitancy in Western countries may be different from non-Western countries [16].

The outcomes of the current study have implications for the vaccination programs. Subgroups were identified that are more possible to refuse or delay vaccination, thus improving the importance of providing details that the people perceive as obvious and comprehensible by various channels. Vaccine acceptance and hesitancy should be regularly surveyed and assessed to change strategies as considered essential. Targeted data should be discharged by trusted individuals, which may vary according to the subgroup.

It is necessary for governments and managers that first try to building the trust of the general population to the vaccination, and then starting the mandatory vaccination. Two strategies for building public trust in vaccination are educational programs that are localized and a modelling system that pre-figures honesty. The said steps can somehow increase authorities' strategic communication actions in building public trust that is important in facilitating vaccination against COVID-19 [57]. More studies are required to better understand the cultural and spiritual factors contributing to the variations in willingness to COVID-19 vaccines [12].

Strengths and limitations

Strengths include the large probability-based representative sample in Iran. The research has limitations. The study cannot infer causality due to the cross-sectional study type; however, the study included variables likely to be necessary for vaccine trust. A study may reach different outcomes when COVID-19 cases and mortality rate are low, and without lockdown, might yield different results. The study did not include participants who are institutionalized (e.g. prisoners), prominently tough to access (e.g. homeless), or those illiterate; specific studies are required for these people. The study examined vaccination trust. Actual uptake may be different, however, it is possible that representatives correlated with trust will affect uptake. We used the WhatsApp platform, and so it may miss people from lower socioeconomic classes such as farmers, those with lower educational attainment, and those who were illiterate. But, according to IndexMundi, the literacy rate of adults in Iran (aged 15 and above) was 85.5%.

CONCLUSIONS

COVID-19 vaccination acceptance is high in Iran and also, trust in an Iranian Covid-19 vaccine is higher than a foreign vaccine. The people with the most trust in government, high income, male gender, high well-being, and education have more acceptance of the Covid-19 vaccine. The strongest predictors of Iranian COVID-19 vaccine acceptance were "trust in government", income, well-being, and education. The strongest predictors of Iranian COVID-19 vaccine acceptance were "trust in government", gender and education.

ACKNOWLEDGEMENTS

I am very grateful to all those who helped me in conducting this research, especially the dear participants.

Conflict of interests

There is no conflict of interest in this research.

ETHICAL CONSIDERATION

This research has succeeded in obtaining the code of ethics from the Islamic Azad University of Tehran West Branch with IR.IAU.WT.REC.1402.006 ID.

REFERENCES

1. Dong E., Du H., Gardner L., 2020. An interactive web-based dashboard to track COVID-19 in real time. The Lancet infectious diseases. 20(5), 533-534.

2. Lim W.S., Liang C.K., Assantachai P., Auyeung T.W., Kang L., Lee W.J., Lim J.Y., Sugimoto K., Akishita M., Chia S.L., 2020. COVID-19 and older people in Asia: Asian Working Group for Sarcopenia calls to action. Geriatrics & gerontology international. 20(6), 547-558. 3. Le T.T., Cramer J.P., Chen R., Mayhew S., 2020. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov. 19(10), 667-668.

4. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 383(27), 2603-2615.

5. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 397(10269), 99-111.

6. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 384(5), 403-416.

7. Sadoff J., Gray G., Vandebosch A., Cárdenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., 2021. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. New England Journal of Medicine. 384(23), 2187-2201.

8. Abdool Karim S.S., de Oliveira T., 2021. New SARS-CoV-2 variants—clinical, public health, and vaccine implications. New England Journal of Medicine. 384(19), 1866-1868.

9. Del Rio C., Malani P., 2021. COVID-19 in 2021— Continuing Uncertainty. JAMA. 325(14), 1389-1390.

10. Fine P., Eames K., Heymann D.L., 2011. "Herd immunity": A rough guide. Clinical infectious diseases. 52(7), 911-916.

11. Neumann-Böhme S., Varghese N.E., Sabat I., Barros P.P., Brouwer W., van Exel J., Schreyögg J., Stargardt T., 2020. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. The European Journal of Health Economics. 21, 977-982.

12. Chew N.W., Cheong C., Kong G., Phua K., Ngiam J.N., Tan B.Y., Wang B., Hao F., Tan W., Han X., 2021. An Asia-Pacific study on healthcare workers' perceptions of, and willingness to receive, the COVID-

19 vaccination. International Journal of Infectious Diseases. 106, 52-60.

 Smith N., Graham T., 2019. Mapping the antivaccination movement on Facebook. Information, Communication & Society. 22(9), 1310-1327.

14. Scheres J., Kuszewski K., 2019. The Ten Threats to Global Health in 2018 and 2019. A welcome and informative communication of WHO to everybody. Zeszyty Naukowe Ochrony Zdrowia. Zdrowie Publiczne i Zarzadzanie. 17(1), 2-8.

15. Caron-Poulin L., Rotondo J., Cutler J., Desai S., Squires S., 2017. Burden and deaths associated with vaccine preventable diseases in Canada, 2010-2014. Online Journal of Public Health Informatics. 9(1). doi: 10.5210/ojphi.v9i1.7676

16. Murphy J., Vallières F., Bentall R.P., Shevlin M., McBride O., Hartman T.K., McKay R., Bennett K., Mason L., Gibson-Miller J., 2021. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nature Communications. 12(1), 1-15.

17. Skoda E.M., Teufel M., Stang A., Jöckel K.H., Junne F., Weismüller B., Hetkamp M., Musche V., Kohler H., Dörrie N., 2020. Psychological burden of healthcare professionals in Germany during the acute phase of the COVID-19 pandemic: Differences and similarities in the international context. Journal of Public Health. 42(4), 688-695.

18. Organization W.H., 2017. Vaccination and trust: how concerns arise and the role of communication in mitigating crises. In Vaccination and trust: how concerns arise and the role of communication in mitigating crises.

19. Blanchard J.I., Johnson C., McIntyre M., Crowcroft N.S., McLellan A., 2020. A pre and post intervention study measuring the effect of interactive education on adolescent perceptions of vaccines, vaccine safety and disease risk. Journal of Public Health. 42(3), e272-e277.

20. Salali G.D., Uysal M.S., 2020. COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey. Psychological Medicine. 52(15), 3750-3752.

21. Ali S.H., Foreman J., Tozan Y., Capasso A., Jones A.M., 2020. DiClemente, R. J., Trends and predictors of COVID-19 information sources and their relationship with knowledge and beliefs related to the pandemic:

nationwide cross-sectional study. JMIR Public Health and Surveillance. 6(4), e21071.

22. Chou W.Y.S., Budenz A., 2020. Considering emotion in COVID-19 vaccine communication: addressing vaccine hesitancy and fostering vaccine confidence. Health Communication. 35(14), 1718-1722.

23. Mariani R., Renzi A., Di Trani M., Trabucchi G., Danskin K., Tambelli R., 2020. The impact of coping strategies and perceived family support on depressive and anxious symptomatology during the coronavirus pandemic (COVID-19) lockdown. Frontiers in Psychiatry. 11, 1195.

24. Ferrucci R., Averna A., Marino D., Reitano M.R., Ruggiero F., Mameli F., Dini M., Poletti B., Barbieri S., Priori A., 2020. Psychological impact during the first outbreak of COVID-19 in Italy. Frontiers in Psychiatry. 11, 559266.

25. Larson H.J., Jarrett C., Eckersberger E., Smith D.M., Paterson P., 2014. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012. Vaccine. 32(19), 2150-2159.

26. Moccia G., Carpinelli L., Savarese G., Borrelli A., Boccia G., Motta O., Capunzo M., De Caro F., 2021. Perception of Health, Mistrust, Anxiety, and Indecision in a Group of Italians Vaccinated against COVID-19. Vaccines. 9(6), 612.

27. Fadda M., Albanese E., Suggs L.S., 2020. When a COVID-19 vaccine is ready, will we all be ready for it? International Journal of Public Health. 65, 711-712.

28. Spitzer R., Kroenke K., Williams J., 2006. Generalized anxiety disorder 7-item (GAD-7) scale. Arch Intern Med. 166, 1092-7.

29. Kroenke K., Spitzer R.L., Williams J.B., 2001. The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine. 16(9), 606-613.

30. Besharat M., 2009. Reliability and Validity of a short form of the Mental Health Inventory in an Iranian population. Scientific Journal of Forensic Medicine. 15(2), 87-91.

31. Veit C.T., Ware J.E., 1983. The structure of psychological distress and well-being in general populations. Journal of Consulting and Clinical Psychology. 51(5), 730.

32. Sanche S.L.Y., Xu C, 2020. Romero-Severson E, Hengartner N, Ke R. , High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 26(7), 1470–1477.

33. Li J., Aipire A., Zhao H., Yuan P., Li J., 2019. Pleurotus ferulae polysaccharides improve the antitumor efficacy of therapeutic human papillomavirus dendritic cell-based vaccine. Human Vaccines & Immunotherapeutics. 15(3), 611-619.

 Bendau A., Plag J., Petzold M.B., Ströhle A., 2021.
 COVID-19 vaccine hesitancy and related fears and anxiety. International Immunopharmacology. 97, 107724.

35. Malik A., McFadden S., Elharake J., Omer S., 2020. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020, 26.

36. Reiter P.L., Pennell M.L., Katz, M.L., 2020. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine. 38(42), 6500-6507.

37. Kaadan M.I., Abdulkarim J., Chaar M., Zayegh O., Keblawi M.A., 2021. Determinants of COVID-19 vaccine acceptance in the Arab world: a cross-sectional study. Global Health Research and Policy. 6(1), 1-7.

38. Runciman C., Roberts B., Alexander K., Bohler-Muller N., Bekker M., 2021. UJ-HSRC COVID-19 democracy survey: Willingness to take a Covid-19 vaccine: A research briefing. University of Johannesburg. Retrieved November. 10, 2021.

39. Bono S.A., Faria de Moura Villela E., Siau C.S., Chen W.S., Pengpid S., Hasan M.T., Sessou P., Ditekemena J.D., Amodan B.O., Hosseinipour M.C., 2021. Factors affecting COVID-19 vaccine acceptance: An international survey among Low-and Middle-Income Countries. Vaccines. 9(5), 515.

40. Lazarus J.V., Ratzan S., Palayew A., Gostin L.O., Larson H.J., Rabin K., Kimball S., El-Mohandes A., 2020. Hesitant or not? A global survey of potential acceptance of a COVID-19 vaccine. Nature Medicine. 27(2), 225-228.

41. Sallam M., Dababseh D., Eid H., Al-Mahzoum K., Al-Haidar A., Taim D., Yaseen A., Ababneh N.A., Bakri F.G., Mahafzah A., 2021. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: A study in Jordan and Kuwait among other Arab countries. Vaccines. 9(1), 42.

42. McNally R., Mair P., Mugno B., Riemann B., 2017.
Co-morbid obsessive–compulsive disorder and depression: A Bayesian network approach. Psychological Medicine. 47(7), 1204-1214.

43. Lee T.T., 2010. Why they don't trust the media: An examination of factors predicting trust. American behavioral scientist. 54(1), 8-21.

44. Tomljenovic H., Bubic A., Erceg N., 2021. Contribution of rationality to vaccine attitudes: Testing two hypotheses. Journal of Behavioral Decision Making. 35(2), e2260.

45. Fridman I., Lucas N., Henke D., Zigler C.K., 2020. Association between public knowledge about COVID-19, trust in information sources, and adherence to social distancing: cross-sectional survey. JMIR public health and surveillance. 6(3), e22060.

46. Painter M., Qiu T., 2020. Political beliefs affect compliance with covid-19 social distancing orders. Covid Economics. 4, 103-123.

47. Karić T., Međedović J., 2021. COVID-19 Conspiracy beliefs and containment-related behaviour: the role of political trust. Personality and Individual Differences. 175, 110697.

48. Head K.J., Kasting M.L., Sturm L.A., Hartsock J.A., Zimet G.D.A., 2020. National survey assessing SARS-CoV-2 vaccination intentions: Implications for future public health communication efforts. Science Communication. 42(5), 698-723.

49. Sun R., Wang X., Lin L., Zhang N., Li L., Zhou X., 2021. The impact of negative emotional reactions on parental vaccine hesitancy after the 2018 vaccine event in China: A cross-sectional survey. Human Vaccines & Immunotherapeutics. 17(9), 3042-3051.

50. Eyllon M., Dang A.P., Barnes J.B., Buresh J., Peloquin G.D., Hogan A.C., Nordberg S.S., 2022. Associations between psychiatric morbidity and COVID-19 vaccine hesitancy: An analysis of electronic health records and patient survey. Psychiatry Research. 307, 114329. 51. Madison A.A., Shrout M.R., Renna M.E., Kiecolt-Glaser J.K., 2021. Psychological and behavioral predictors of vaccine efficacy: Considerations for COVID-19. Perspectives on Psychological Science. 16(2), 191-203.

52. Kwok K.O., Li K.K., Wei W.I., Tang A., Wong S.Y.S., Lee S.S., 2021. Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey. International Journal of Nursing Studies. 114, 103854.

53. Conway L., Woodard S.R., Zubrod A., Chan L., 2020. Why are conservatives less concerned about the coronavirus (COVID-19) than liberals? Testing experiential versus political explanations. PsyArXiv Preprints. DOI:10.31234/osf.io/fgb84

54. Tal O., Ne'eman Y., Sadia R., Shmuel R., Schejter E., Bitan M., 2021. Parents' attitudes toward children's vaccination as a marker of trust in health systems. Human Vaccines & Immunotherapeutics. 17(11), 4518-4528.

55. Hornsey M.J., Finlayson M., Chatwood G., Begeny C.T., 2020. Donald Trump and vaccination: The effect of political identity, conspiracist ideation and presidential tweets on vaccine hesitancy. Journal of Experimental Social Psychology. 88, 103947.

56. Zarocostas J., 2004. UNICEF taps religious leaders in vaccination push. The Lancet. 363(9422), 1709.

57. Vergara R.J.D., Sarmiento P.J.D., Lagman J.D.N., 2021. Building public trust: a response to COVID-19 vaccine hesitancy predicament. Journal of Public Health. 43(2), e291-e292.

58. Iyengar S., Lelkes Y., Levendusky M., Malhotra N., Westwood S.J., 2019. The origins and consequences of affective polarization in the United States. Annual Review of Political Science. 22, 129-146.

59. Druckman J.N., Klar S., Krupnikov Y., Levendusky M., Ryan J.B., 2020. How affective polarization shapes Americans' political beliefs: A study of response to the COVID-19 pandemic. Journal of Experimental Political Science. 8(3), 223-234.